Etanercept treatment in corticosteroid-dependent myasthenia gravis

ROWIN J., MERIGGIOLI M., Tuzun E., LEURGANS S., CHRISTADOSS P.

NEUROLOGY, cilt.63, sa.12, ss.2390-2392, 2004 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 63 Sayı: 12
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1212/01.wnl.0000147242.92691.71
  • Dergi Adı: NEUROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2390-2392
  • İstanbul Üniversitesi Adresli: Evet

Özet

The authors report a prospective pilot trial of etanercept in corticosteroid-dependent autoimmune myasthenia gravis. Eleven patients were enrolled, with eight completing the 6-month trial. Two patients were withdrawn owing to disease worsening, and one patient was withdrawn because of an erythematous skin rash. Six of the eight patients who completed the trial improved, based on quantitative measures of muscle strength and lowering of corticosteroid requirement.